MITOXCEL
LIVE

Serial Number

99230621

Owner

SENOTHERAPEUTIX, Inc.

Attorney

Jared L. DuJack

Filing Date

Jun 12, 2025

Add to watchlist:

No watchlists yet
View on USPTO

MITOXCEL Trademark

Serial Number: 99230621

MITOXCEL is a trademark filed by SENOTHERAPEUTIX, Inc. on June 12, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

SENOTHERAPEUTIX, Inc.

9511 Collins Avenue #1403
Surfside, FL 33154

Entity Type: 03

Trademark Details

Filing Date

June 12, 2025

Registration Date

Not Registered

Published for Opposition

May 5, 2026

Goods & Services

Synthesized peptides for the treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for the prevention of and treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for gene therapy for the treatment of age-related disorders; Pharmaceutical preparations for gene therapy for the treatment of cancer; Medicated skin preparation for use in treating skin conditions, aging, mitochondrial conditions, and senescent cells

Medical research services; Medical research in the field of mitochondrial health and mitochondrial disease; Medical research services in the field of metabolic health and metabolic conditions; Medical research services in the field of anti-aging; Medical research services in the field of senescent cells; Medical research services in the field of age-related disorders; Medical research services in the field of neurodegenerative health and neurodegenerative disease; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Gene therapy research; Testing of pharmaceuticals for cell and gene therapies; Development of pharmaceuticals for cell and gene therapies; Pharmaceutical research in the field of mitochondrial disease; Pharmaceutical research in the field of metabolic conditions; Pharmaceutical research in the field of neurodegenerative disease

Medical services, namely, anti-aging services; Medical services, namely, providing preventative care and treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Medical services in the field of mitochondrial health and mitochondrial disease; Medical services in the field of metabolic health and metabolic conditions; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical services in the field of neurodegenerative health and neurodegenerative disease; Medical advisory services; Medical testing services; Medical testing services relating to the diagnosis and treatment of disease

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 5, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 5, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 29, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 7, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 16, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 16, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 16, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Dec 15, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 15, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 17, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 17, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 17, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 10, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 15, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jun 12, 2025 MAFR
NEW APPLICATION ENTERED
Jun 12, 2025 NWAP